Effects of high and low doses of methimazole in patients with Graves' thyrotoxicosis

Benker, G.; Reinwein, D.; Creutzig, H.; Hirche, H.; Alexander, W. D.; McCruden, D. C.; Galvan, G; Kahaly, George J.; Beyer, J.; Lazarus, John; Schatz, H.; Schleusener, H.; Schneider, H.-G.; Ziegler, R.; Tegler, Lennart; Nilson, O. R.

doi:10.1530/acta.0.114s312

Cited by 14 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, several studies have shown that the small starting dose of MMI is sufficient to treat hyperthyroidism [7,8,10]. In 1986, Shiroozu et al [9] reported that a single daily dose of 15 mg of MMI was as effective as 10 mg administered 3 times daily or 30 mg administered once daily.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Hyperthyroidism with a Small Single Daily Dose of Methimazole: A Prospective Long-Term Follow-Up Study.

et al. 1997

View full text Add to dashboard Cite

Abstract.A prospective long-term follow-up study was performed with conventional divided doses (group C:10 mg 3 times daily, N=58) and a small single daily dose (group S:15 mg once daily, N=54) of methimazole (MMI) for the treatment of Graves' hyperthyroidism. Within 8 weeks, almost 80% of the patients in both groups became euthyroid. The mean time required to achieve a euthyroid state was 5.6 ± 2.7 weeks in group C and 5.8 ± 3.1 in group S. TSH binding inhibitor immunoglobulin (TBII) levels before therapy were 44.2 ± 22.7% and 47.1 ± 23.9% in group C and group S, respectively. A similar gradual fall in TBII levels was observed in both groups over a two-year period of treatment. MMI doses were gradually reduced to a maintenance dose (5 mg daily) after the patients became euthyroid. The patients were treated for 28 ± 9 months and were followed up after therapy was stopped (observation period in patients who remained in remission was 12-130 (75 ± 34) months and the interval to relapse in reccured cases was 1-98 (20 ± 27) months).The rates of recurrence in group C were 41% at 1 yr, 54% at 2 yrs, 56% at 4 yrs and 61% at 6 yrs. In group S, these were 44%, 53%, 56% and 63%, respectively. No differences between relapse rates were observed with the two different dosage regimens. Adverse effects occurred more frequently in group C patients (24%) than in group S patients (13%). These results show that there is no difference in the clinical and immunological course or in the long-term remission rate of Graves' hyperthyroidism when the treatment is initiated with either a small single daily dose (15 mg) or the conventional regimen (10 mg 3 times daily).

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Hyperthyroidism with a Small Single Daily Dose of Methimazole: A Prospective Long-Term Follow-Up Study.

et al. 1997

View full text Add to dashboard Cite

show abstract

“…TSAb activity was negative in 82.6% of remission patients and in 33.3% of relapsed patients. On the other hand, TSAb was positive in 17 suppressibility. The serum Tg concentrations did not differ between remission and relapsed patients.…”

Section: Remission and Relapse Ratementioning

confidence: 86%

“…The MMI and T3 were discontinued after the patient had maintained a FT4I below the normal range (12,16) for at least 6 months. The duration of treatment for both groups was 15 ± 4.1 (range [13][14][15][16][17][18][19][20][21][22] months. The patients were followed up clinically and biochemically after cessation of therapy for 18 ± 3 (range 13-49) months.…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Serum Thyroid-Stimulating Antibody, Thyroglobulin Levels, and Thyroid Suppressibility Measurement as Predictors of the Outcome of Combined Methimazole and Triiodothyronine Therapy in Graves' Disease

Werner¹,

Romaldini²,

Farah³

et al. 1991

Thyroid

View full text Add to dashboard Cite

The value of the criteria used to anticipate the outcome of treatment of Graves' hyperthyroid patients with methimazole (MMI) remains controversial. We have reported that high MMI doses combined with T3 administration was correlated with higher remission rates. In this study, we used the lowest MMI dose able to control the hyperthyroidism, keeping the free T4 index (FT4I) values below the normal range throughout treatment, and compared the results with patients treated with a high MMI regimen. Both groups received T3. We also evaluated the usefulness of goiter size, serum thyroid-stimulating antibody (TSAb: adenylate cyclase stimulation in human thyroid membrane), thyroglobulin (Tg) levels, and the T3 suppressibility of 24 h RAIU as prognostic markers for the outcome of Graves' disease therapy. Twenty-four Graves' hyperthyroid patients were treated with high MMI dose (mean +/- SD 60 +/- 19, range 40-120 mg daily), and 25 patients received low MMI dose (17 +/- 4.3, 5-20 mg daily). T3, 75 micrograms daily, was given to both groups of patients for 15 +/- 4 (13-22) months of treatment. After cessation of drug therapy, 31 patients (63%) remained euthyroid for 18 +/- 3 (13-49) months of follow-up, 15 (62.5%) and 16 (64%) patients in the high and low dose groups, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…Epidemiologische Daten geben eine Prävalenz zwischen 0,05% und 0,2% an[15]. Umgekehrt untersuchten andere Autoren[16] die Häufigkeit einer Schwangerschaft bei hyperthyreoten Frauen unter thyreostatischer Therapie. Die Prävalenz lag bei 2%.…”

unclassified

Aktuelle Schilddrüsendiagnostik und -therapie bei Fertilitätsstörungen und Schwangerschaft

Fink¹,

Hintze²

2006

Med Klin

View full text Add to dashboard Cite

Effects of high and low doses of methimazole in patients with Graves' thyrotoxicosis

Cited by 14 publications

References 0 publications

Treatment of Hyperthyroidism with a Small Single Daily Dose of Methimazole: A Prospective Long-Term Follow-Up Study.

Treatment of Hyperthyroidism with a Small Single Daily Dose of Methimazole: A Prospective Long-Term Follow-Up Study.

Serum Thyroid-Stimulating Antibody, Thyroglobulin Levels, and Thyroid Suppressibility Measurement as Predictors of the Outcome of Combined Methimazole and Triiodothyronine Therapy in Graves' Disease

Aktuelle Schilddrüsendiagnostik und -therapie bei Fertilitätsstörungen und Schwangerschaft

Contact Info

Product

Resources

About